TORONTO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV: EMC, OTCQX: EMMBF) (“Emblem” or the “Company”)
announced that the board of directors of the Company has approved the granting of 350,000 incentive stock options (the “Options”)
to certain officers of the Company. The Options are exercisable at a price of $1.60 per share for a period of five years and
are subject to vesting as to one-third the number of Options granted on each of September 25, 2019, 2020 and 2021.
About Emblem
Emblem, through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of
medical cannabis and cannabis derivatives in Canada under the Access to Cannabis for Medical Purposes Regulations.
Emblem’s state-of-the-art indoor cannabis cultivation facility and research and development laboratory is located in Paris,
Ontario. Led by an experienced management team of healthcare executives, accomplished marketing professionals, and cannabis
experts, Emblem is focused on driving shareholder value through product innovation, brand relevance, and access to patient and
consumer channels. Emblem is also the ultimate parent company of GrowWise Health Ltd., one of Canada’s leading medical cannabis
education services. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange. For more information, please visit
www.emblemcorp.com.
For media inquiries, please contact:
Morgan Cates
H+K Strategies
416.413.4649
morgan.cates@hkstrategies.ca
For other inquiries, please contact:
Ethan Karayannopoulos
Investor Relations
Emblem Corp.
647.748.9696
ethank@emblemcorp.com
Alex Stojanovic
Chief Financial Officer
Emblem Corp.
416.923.1331
alexs@emblemcorp.com
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein
as "forward-looking statements") within the meaning of applicable Canadian securities laws. All statements other than statements of
present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the
use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing",
"estimate", "outlook", "expect", "may", "will", "project", "should" or similar words, including negatives thereof, suggesting
future outcomes. Management of the Company believes the expectations reflected in such forward-looking statements are reasonable as
of the date hereof but no assurance can be given that these expectations will prove to be correct and such forward-looking
statements should not be unduly relied upon. Various material factors and assumptions are typically applied in drawing conclusions
or making the forecasts or projections set out in forward-looking statements. Those material factors and assumptions are based on
information currently available to the Company, including data from publicly available governmental sources as well as from market
research and industry analysis and on assumptions based on data and knowledge of this industry which Emblem believes to be
reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics,
such data is inherently imprecise. While Emblem is not aware of any misstatement regarding any industry or government data
presented herein, the medical marijuana industry involves risks and uncertainties and is subject to change based on various
factors.
Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and
unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company's actual
performance and results to differ materially from any projections of future performance or results expressed or implied by such
forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company's
December 31, 2017 Management's Discussion and Analysis, which has been filed with the Canadian Securities Administrators and
available on www.sedar.com. Any forward-looking statements are made as of the date hereof and, except as
required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information,
subsequent or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of
the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
